Walter Ezeigbo, MD
Family Medicine · Winston Salem, NCNPI 1306839659
Payments from drug & device makers
Across 382 payments — averaging $20.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- AstraZeneca$2K
- Lilly USA, LLC$1K
- Boehringer Ingelheim$338
- Bayer$291
- Sanofi-aventis U.S. LLC$263
- plus $2K from 31 others
What the payments were for
- Food & beverage$7,848100%
- Education$210%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 146 | $2,335 |
| AstraZeneca | 61 | $1,727 |
| Lilly USA, LLC | 44 | $1,079 |
| Boehringer Ingelheim | 15 | $338 |
| Bayer | 12 | $291 |
| Sanofi-aventis U.S. LLC | 15 | $263 |
| GSK | 13 | $218 |
| Pfizer | 11 | $169 |
| Amgen | 4 | $158 |
| Merck | 8 | $128 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $127 |
| Acadia Pharmaceuticals Inc | 1 | $125 |
| AbbVie | 2 | $124 |
| Antares Pharma, Inc. | 5 | $114 |
| Halozyme Inc | 6 | $105 |
| Daiichi Sankyo Inc. | 4 | $68 |
| Eisai Inc. | 3 | $55 |
| Verity Pharmaceuticals Inc. | 2 | $41 |
| Tolmar, Inc. | 2 | $35 |
| Corcept Therapeutics | 1 | $34 |
| Acerus Pharmaceuticals Corporation | 2 | $31 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $31 |
| Otsuka America Pharmaceutical, Inc. | 1 | $30 |
| Abbott | 1 | $30 |
| Biohaven Pharmaceuticals, Inc. | 1 | $26 |
| Novartis | 1 | $21 |
| Tris Pharma Inc | 1 | $19 |
| Sanofi Pasteur Inc. | 1 | $18 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Exact Sciences | 1 | $16 |
| Astellas Pharma US Inc | 1 | $15 |
| Ironshore Pharmaceuticals Inc. | 1 | $15 |
| Paratek Pharmaceuticals, Inc. | 1 | $14 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $13 |
| Currax Pharmaceuticals LLC | 1 | $12 |
| Neos Therapeutics, LP | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,869 in reported general payments places this provider in the 90th percentile of 3,444 family medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 95 | $106,629 |
| MounjaroTirzepatide | 76 | $85,548 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 63 | $65,608 |
| Xigduo XrDapaglifloz Propaned/Metformin | 55 | $63,426 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 58 | $44,382 |
| FarxigaDapagliflozin Propanediol | 51 | $43,011 |
| JardianceEmpagliflozin | 26 | $27,981 |
| EliquisApixaban | 27 | $27,235 |
| KerendiaFinerenone | 25 | $26,856 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 21 | $15,068 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 42 | $12,970 |
| VyvanseLisdexamfetamine Dimesylate | 28 | $11,294 |
| Breo ElliptaFluticasone/Vilanterol | 15 | $6,107 |
| Spiriva RespimatTiotropium Bromide | 11 | $5,499 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 19 | $4,246 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $2,335 | $106,62995 claims |
| Boehringer IngelheimSynjardy Xr, Jardiance, Spiriva Respimat | $338 | $99,089100 claims |
| Lilly USA, LLCMounjaro | $1,079 | $85,54876 claims |
| GSKTrelegy Ellipta, Arexvy, Breo Ellipta, Shingrix | $218 | $67,705134 claims |
| AstraZenecaFarxiga | $1,727 | $43,01151 claims |
| PfizerEliquis | $169 | $27,23527 claims |
| BayerKerendia | $291 | $26,85625 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $263 | $15,06821 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $31 | $11,29428 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,444 family medicine providers in North Carolina.
Other family medicine in Winston Salem
- David DundeeWinston Salem$633K
- Cressent PresslyWinston Salem$199K
- Ryan MurrayWinston Salem$133K
- Brian WellsWinston Salem$88K
- Lucian VladWinston Salem$82K
- Barton WilliamsWilmington$17.3M
- Alexander MurrayGreensboro$13M
- Arin PiramzadianJacksonville$13M
- Jonathan WilsonHickory$12.7M
- George RaadCharlotte$7.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.